Sanj K. Patel - 01 Apr 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
01 Apr 2025
Net transactions value
-$115,838
Form type
4
Filing time
03 Apr 2025, 17:01:23 UTC
Previous filing
19 Mar 2025
Next filing
09 Apr 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +6,481 +7.7% 90,597 01 Apr 2025 Direct F1
transaction KNSA Class A Ordinary Share Options Exercise +6,238 +6.9% 96,835 01 Apr 2025 Direct F1
transaction KNSA Class A Ordinary Share Tax liability $50,158 -2,304 -2.4% $21.77 94,531 01 Apr 2025 Direct
transaction KNSA Class A Ordinary Share Tax liability $65,680 -3,017 -3.2% $21.77 91,514 01 Apr 2025 Direct
holding KNSA Class A Common Share 109,795 01 Apr 2025 Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Award $0 +137,638 $0.000000 137,638 01 Apr 2025 Class A Ordinary Share 137,638 $21.77 Direct F2
transaction KNSA Restricted Share Unit Award $0 +34,435 $0.000000 34,435 01 Apr 2025 Class A Ordinary Share 34,435 Direct F1, F3
transaction KNSA Performance Share Unit Award $0 +68,869 $0.000000 68,869 01 Apr 2025 Class A Ordinary Share 68,869 Direct F4, F5
transaction KNSA Restricted Share Unit Options Exercise $0 -6,481 -33% $0.000000 12,962 01 Apr 2025 Class A Ordinary Share 6,481 Direct F1, F6
transaction KNSA Restricted Share Unit Options Exercise $0 -6,238 -25% $0.000000 18,712 01 Apr 2025 Class A Ordinary Share 6,238 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2025.
F3 The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025.
F4 Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.
F5 Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply.
F6 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023.
F7 The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter.